Personalis is expanding its Next platform by adding several new features with the aim of supporting better understanding of the interactions between tumors and the immune system.
The Next platform now includes the following updated features:
- InfiltrateID, an analytics module that leverages augmented gene expression data from the Next transcriptome to detect the presence of eight immune cell populations within a tumor sample.
- RepertoireID, which now incorporates characterizing the B-cell receptor repertoire, to complement the previously released T-cell receptor repertoire feature.
- Sherpa, which helps with the company's panallelic neoantigen prediction algorithm.
